ACT-389949 200 mg

DRUG2 trials

Sponsors

Idorsia Pharmaceuticals Ltd.

Conditions

Healthy Subjects

Phase 1

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

CompletedNCT02099201

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2012-11-30End: 2013-05-31Updated: 2018-07-10

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

CompletedNCT02099071

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2011-11-30End: 2012-05-31Updated: 2018-07-10